Glycine receptor subunit alpha-2 Inhibitors (IC50, Ki)

Structure ▲ ▼	Compound Name ▲ ▼	Standard Type ▲ ▼	Standard Values (in nM) ▲ ▼
	Ginkgolide-B	IC50	3700.0 [1]
	Ginkgolide A	IC50	2100.0 [1]
	Ginkgolide M	IC50	1300.0 [1]
	(1R,3R,6R,7S,8S,9S,11S,12S,13S,16S,17S)-8-Tert-butyl-6,9,12,17-tetrahydroxy-13-methyl-2,4,15,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.012,16]nonadecane-5,14,18-trione	IC50	8200.0 [1]
	(1R,3R,6R,7S,8S,9S,10R,11R,12R,13S,16S,17R)-8-Tert-butyl-9-chloro-6,12,17-trihydroxy-16-methyl-2,4,14,18-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,19-trione	IC50	13000.0 [1]
	(1R,3R,6R,7S,8S,9S,10S,11R,12R,13S,16S,17R)-9-Azido-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,18-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,19-trione	IC50	29000.0 [1]
	(6R,8S,11S,16R,17S)-8-Tert-butyl-6,16,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione	IC50	100000.0 [1]
	(1S,8S,11S,13S,16S,17R)-8-Tert-butyl-17-hydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,6,15,18-tetrone	IC50	100000.0 [1]
	10-Acetoxy-ginkgolide B	IC50	100000.0 [1]
	[(1R,6R,8S,11S,13S,16R,17S)-8-Tert-butyl-16-methyl-5,15,18-trioxo-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-6-yl] acetate	IC50	100000.0 [1]
	10-Methoxymethyloxy-ginkgolide A	IC50	100000.0 [1]
	(1S,6R,8S,9R,11S)-8-Tert-butyl-6,9-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadeca-12,16-diene-5,15,18-trione	IC50	100000.0 [1]
	Methyl (2R)-2-[(1S,2R,3S,6S,8S,10S)-10-tert-butyl-2-hydroxy-16-methoxy-3-methyl-4,14-dioxo-5,13,15-trioxapentacyclo[7.5.2.01,8.02,6.08,12]hexadecan-9-yl]-2-methoxyacetate	IC50	100000.0 [1]
	(1R,2R,3S,6S,8S,10R,11R)-10-Tert-butyl-2,11,16-trihydroxy-3-methyl-5,13,15-trioxapentacyclo[7.5.2.01,8.02,6.08,12]hexadecane-4,14-dione	IC50	100000.0 [1]
	(1S,2R,3S,6S,8S,10R)-10-Tert-butyl-2-hydroxy-3-methyl-5,13,15-trioxapentacyclo[7.5.2.01,8.02,6.08,12]hexadecane-4,14,16-trione	IC50	100000.0 [1]
	[(1R,6R,8S,11R)-8-Tert-butyl-13-methoxy-5,15,16-trioxo-2,4,14,17-tetraoxapentacyclo[8.5.2.01,11.03,7.07,11]heptadecan-6-yl] acetate	IC50	100000.0 [1]
	(1R,6R,8S,11S)-8-Tert-butyl-6,13-dimethoxy-2,4,14,17-tetraoxapentacyclo[8.5.2.01,11.03,7.07,11]heptadecane-5,15,16-trione	IC50	100000.0 [1]
	Methyl (2E)-2-[(1R,6R,8S,11S)-8-tert-butyl-6-hydroxy-5,15-dioxo-2,4,16-trioxapentacyclo[8.4.2.01,11.03,7.07,11]hexadecan-14-ylidene]propanoate	IC50	100000.0 [1]
	Methyl 2-[(1R,6R,8S,11S,14R)-8-tert-butyl-6-hydroxy-5,15-dioxo-2,4,16-trioxapentacyclo[8.4.2.01,11.03,7.07,11]hexadecan-14-yl]propanoate	IC50	100000.0 [1]
	(1S,6R,8S,11S,13R,16R,17R)-8-Tert-butyl-6,17-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,18-dione	IC50	100000.0 [1]
	(1S,6R,8S,11S,13S,16R,17R)-8-Tert-butyl-6,17-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-18-one	IC50	100000.0 [1]
	(1R,6R,8S,11S,13S,16R,17R)-8-Tert-butyl-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-6,17-diol	IC50	100000.0 [1]
	(1S,6R,8S,9S,11R,12R,13S,16S,17R)-8-Tert-butyl-6,12,17-trihydroxy-16-methyl-9-(methylamino)-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione	IC50	100000.0 [1]
	(1S,6R,8S,9S,11R,12R,13S,16S,17R)-8-Tert-butyl-9-(ethylamino)-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione	IC50	100000.0 [1]
	[(1S,6R,8S,9S,11R,12R,13S,16S,17R)-8-Tert-butyl-6,12,17-trihydroxy-16-methyl-5,15,18-trioxo-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-9-yl] 2-phenylacetate	IC50	100000.0 [1]
	(1S,6R,8S,9S,11R,12R,13S,16S,17R)-8-Tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione	IC50	100000.0 [1]
	[(1S,6R,8S,9S,11R,12R,13S,16S,17R)-8-Tert-butyl-6,12,17-trihydroxy-16-methyl-5,15,18-trioxo-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-9-yl] acetate	IC50	100000.0 [1]
	(1S,6R,8S,11R,12R,13S,16S,17R)-8-Tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,9,15,18-tetrone	IC50	100000.0 [1]
	[(1S,6R,8S,9R,11S,12R,13S,16S,17R)-8-Tert-butyl-6,12,17-trihydroxy-16-methyl-5,15,18-trioxo-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-9-yl] trifluoromethanesulfonate	IC50	100000.0 [1]
	(1S,3R,6R,7S,8S,9S,11S,12S,13S,16S)-8-Tert-butyl-6,9,12-trihydroxy-13-methyl-2,4,15,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.012,16]nonadecane-5,14,18-trione	IC50	12000.0 [1]
	(3S,8R,12R,16S,17R,21S)-3-Tert-butyl-17-hydroxy-16-methyl-6,9,11,14,20,22-hexaoxaheptacyclo[10.8.1.15,18.04,8.04,21.013,17.018,21]docosane-7,15,19-trione	IC50	12000.0 [1]
	3,14-Didehydroginkgolide A	IC50	9500.0 [1]
	10-Methoxy-ginkgolide C	IC50	7800.0 [1]
	(1R,3R,6R,7S,8S,9S,10R,11R,12R,13S,16S,17R)-8-Tert-butyl-9-fluoro-6,12,17-trihydroxy-16-methyl-2,4,14,18-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,19-trione	IC50	4600.0 [1]

Entire TableStructureCompound NameStandard TypeStandard Values (in nM)

Items per page: 510All1 - 10 of 34 ⟨⟩

---

---

References

This online tool may be cited as follows

MLA	"Quest Database™ Glycine receptor subunit alpha-2 Inhibitors (IC50, Ki)." AAT Bioquest, Inc., 20 Nov. 2024, https://www.aatbio.com/data-sets/glycine-receptor-subunit-alpha-2-inhibitors-ic50-ki.
APA	AAT Bioquest, Inc. (2024, November 20). Quest Database™ Glycine receptor subunit alpha-2 Inhibitors (IC50, Ki). AAT Bioquest. https://www.aatbio.com/data-sets/glycine-receptor-subunit-alpha-2-inhibitors-ic50-ki.
BibTeX	EndNote	RefMan